报价延迟最少15分钟:2026/09/03 15:40 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
20.235 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.14/-4.60
|
|
企业价值
689.91M
|
| 资产负债 |
|
每股账面净值
4.29
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
10.84M
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets. |
